Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nephrol Dial Transplant
Hlavní autoři: Gansevoort, Ron T., Arici, Mustafa, Benzing, Thomas, Birn, Henrik, Capasso, Giovambattista, Covic, Adrian, Devuyst, Olivier, Drechsler, Christiane, Eckardt, Kai-Uwe, Emma, Francesco, Knebelmann, Bertrand, Le Meur, Yannick, Massy, Ziad A., Ong, Albert C.M., Ortiz, Alberto, Schaefer, Franz, Torra, Roser, Vanholder, Raymond, Więcek, Andrzej, Zoccali, Carmine, Van Biesen, Wim
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Cutting-Edge Renal Science
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4762400/
https://ncbi.nlm.nih.gov/pubmed/26908832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv456
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky